Specialty pharmaceutical company, Mallinckrodt, has announced that Dr Nick Matthews and co-investigator Dr Arun Alfred of the Department of Haematology at Rotherham NHS Foundation Trust, UK, are the inaugural recipients of the Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award.
Awards
The winning submission proposed the establishment of whether immunomodulation achieved through extracorporeal photopheresis (ECP) used in treatment of chronic graft-versus-host disease (GVHD) occurs through mediation of in vivo macrophage activation.
Along with the 2018 Investigator Award, the Department of Haematology at Rotherham NHS Foundation Trust will receive an educational grant of €50,000 to support this research.
“It’s an honour to receive the inaugural Investigator Award and we look forward to sharing the outcomes of our work in due course,” said Alfred on receiving the award at the THERAKOS ECP Immunomodulation symposium at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Lisbon, Portugal.
Mallinckrodt award
“Mallinckrodt is a pioneer in ECP immunomodulation and we recently celebrated the 30th anniversary of THERAKOS,” said Dr Steve Romano, executive vice president and chief scientific officer of Mallinckrodt. “We are proud to support the work of those who continue to push boundaries in the field and I congratulate Dr Alfred and his team at the Rotherham NHS Foundation Trust on this recognition.”
The 2019 Advancing ECP Immunomodulation Investigator Award will be open for entries from September 2018.